Yet, CAF plasticity also presents therapeutic opportunities: while pro-tumorigenic subtypes such as ECM CAFs, regulated by YAP1, accelerate cancer progression, anti-tumor subtypes such as Lym CAFs, driven by NF-κB signaling, can recruit and activate CD8+; T cells to restore immune surveillance [17,18]. The gene discussed is YAP1; the disease is neoplasm.